A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma — IMCODE003  

Adenocarcinoma, Pancreatic Ductal Clinical Trial

Official title: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma

• NCT number: NCT05968326
• Study type: Interventional
• Source: Genentech, Inc.
• Contact: Reference Study ID Number: GO44479 https://forpatients.roche.com
• Phone: 888-662-6728 (U.S. Only)
• Email: global-roche-genentech-trials@gene.com
• Status: Recruiting
• Phase: Phase 2
• Start date: October 18, 2023
• Completion date: December 27, 2029